1
|
Chen S, Yan D, Qin A, Deraniyagala RL, Krauss DJ, Chen PY, Stevens CW, Snyder M. Tumor Voxel Dose-Response Matrix Prediction Using Deep Learning. Int J Radiat Oncol Biol Phys 2023; 117:S66-S67. [PMID: 37784549 DOI: 10.1016/j.ijrobp.2023.06.370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Tumor voxel dose-response matrix (DRM) can be assessed using a series of FDG-PET/CT feedback images acquired during radiotherapy. Predicting the tumor voxel DRM earlier is crucial for effectively implementing adaptive treatment management. However, it is also challenging due to FDG uptake dynamic fluctuation in tumor cells. This study investigated the feasibility of predicting tumor voxel DRM during the early treatment weeks using the advanced deep learning (DL) technique. MATERIALS/METHODS Serial FDG-PET/CT images were acquired at the pretreatment (pre-Tx), the 2nd and 4th treatment weeks during standard chemo-radiotherapy (35 × 2 Gy) from each of the 50 patients with head and neck squamous cell carcinomas (HNSCC). The reference value of tumor voxel DRM (DRMref), representing the average metabolic change ratio during the treatment, was determined using a linear regression performed on the standard uptake values (SUV)s obtained at the pre-Tx (SUV0), the 2nd (SUV2) and the 4th (SUV4) treatment weeks following deformable PET/CT image registration. A DL model, 3D residual-Unet with a total of 3.4 million parameters, was trained to predict the tumor voxel DRMref with using the SUV0 and SUV2 matrices as inputs. The performance of the DL model was evaluated using 10-fold cross-validation and was compared to that of a linear regression (LR) model determined on the SUV0 and SUV2 matrices. RESULTS The mean (SD) of the tumor voxel DRMref was 0.46 (0.2) over all 34612 tumor voxels. The predicted tumor voxel DRM was 0.5 (0.38) and 0.46 (0.15) for the LR model and the DL model, respectively. For those resistant voxels (23.7% of all tumor voxels) with a DRMref > 0.6, the DRM deviation was 0.13 (0.4) and -0.11 (0.13) for the LR model and the DL model, respectively. For those sensitive voxels (76.3%) with a DRMref ≤ 0.6, the DRM deviation was 0.01 (0.23) and 0.03 (0.08) for the LR model and the DL model, respectively. CONCLUSION The proposed DL model can predict the tumor voxel DRM with a single FDG-PET feedback image acquired during the 2nd treatment week of radiotherapy for HNSCC patients. The prediction accuracy was improved compared to that of the LR model with a substantial reduction in the variances of the prediction errors. This work demonstrates the great potential of utilizing DL techniques to improve the efficiency of tumor response assessment and adaptive treatment management.
Collapse
Affiliation(s)
- S Chen
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - D Yan
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - A Qin
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - R L Deraniyagala
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - D J Krauss
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - P Y Chen
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - C W Stevens
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - M Snyder
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| |
Collapse
|
2
|
Chen S, Zhao L, Liu P, Qin A, Deraniyagala RL, Stevens CW, Ding X. Deep Learning-Based Dose Prediction Model for Automated Spot-Scanning Proton Arc Planning. Int J Radiat Oncol Biol Phys 2023; 117:e652. [PMID: 37785938 DOI: 10.1016/j.ijrobp.2023.06.2077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Spot-scanning proton arc (SPArc) is a novel technique that employs a planning optimization algorithm to select the energies and positions of spots along a dynamic rotational arc trajectory. The SPArc technique has the potential to achieve superior dose conformality and treatment delivery efficiency over intensity-modulated proton therapy. However, creating such a SPArc plan using existing approaches is time-consuming and computationally extensively. This study investigated the feasibility of using the deep learning (DL) technique to predict the 3D dose distribution of the SPArc treatment plan, leveraging the prior knowledge acquired from conventional intensity-modulated radiation therapy (IMRT) plans. MATERIALS/METHODS A DL model, 3D-Unet with residual connections and attention gates, was trained using an open-source database of CT images, critical structures, and IMRT plans from 340 head and neck cancer patients (HNC) as the base model. Transfer learning technique was applied to fine-tune the model parameters using the SPArc treatment plans created on the HNC patients from an in-house dataset, where the SPArc treatment plans (including control point sampling, energy layer distribution, arc trajectory, etc.,) were optimized using a previously developed iterative approach. The performance of the DL model was evaluated by comparing predicted and planned doses over 17 SPArc treatment plans by using 4-fold cross-validation. RESULTS The SPArc planning time per patient was 8∼12 hours, while the dose prediction time was reduced to 2∼3 minutes using the proposed DL model. The deviation of D95 in the target was (-1.8±1.6) %. The deviation of the mean dose in the parotids, cord, mandible, and brainstem were (2.5±6.5) %, (-0.5±4.3) %, (1.4±3.9) %, and (3.4±8) % of the prescription, respectively. The dice similarity coefficients of the 80%, 70%, and 60% isodose lines were (0.9±0.09), (0.93±0.01), and (0.94±0.01), respectively. CONCLUSION Our results demonstrate that a DL-based dose prediction model can be created with a limited number of SPArc treatment plans through transfer learning. The DL model can directly predict the 3D dose distribution in minutes for automated planning. This study paves the roadmap to develop a quick clinical decision platform for the optimal selection among the multi-treatment modalities.
Collapse
Affiliation(s)
- S Chen
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - L Zhao
- Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI
| | - P Liu
- Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI
| | - A Qin
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - R L Deraniyagala
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - C W Stevens
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| | - X Ding
- Department of Radiation Oncology, Beaumont Health, Royal Oak, MI
| |
Collapse
|
3
|
Ohri N, Jolly S, Cooper B, Kabarriti R, III WRB, Klein J, Viswanathan S, Kaufman R, Shum E, Sabari J, Cheng H, Gucalp R, Castellucci E, Qin A, Gadgeel S, Halmos B. The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT). Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Ku G, Di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg Z, Ajani J, Chao J, Barlaskar F, Kawaguchi Y, Qin A, Singh J, Meinhardt G, Van Cutsem E. 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
5
|
Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, Chang DY, Macpherson E, Qin A, Singh J, Taitt C, Shire N, Camidge DR. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022; 7:100554. [PMID: 35963179 PMCID: PMC9434416 DOI: 10.1016/j.esmoop.2022.100554] [Citation(s) in RCA: 63] [Impact Index Per Article: 31.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 06/10/2022] [Accepted: 07/04/2022] [Indexed: 11/28/2022] Open
Abstract
Introduction This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXd. Methods Patients who received T-DXd across nine studies were included. Investigator-assessed ILD/pneumonitis events were retrospectively reviewed by an independent adjudication committee; events adjudicated as drug-related ILD/pneumonitis are summarized. Results The analysis included 1150 patients (breast cancer, 44.3%; gastric cancer, 25.6%; lung cancer, 17.7%; colorectal cancer, 9.3%; other cancer, 3.0%). Median treatment duration was 5.8 (range, 0.7-56.3) months, with a median of 4 (range, 1-27) prior lines of therapy. The overall incidence of adjudicated drug-related ILD/pneumonitis was 15.4% (grade 5, 2.2%). Most patients with ILD/pneumonitis experienced low-grade events (grade 1 or 2, 77.4%); 87.0% had their first event within 12 months [median, 5.4 (range, <0.1-46.8) months] of their first dose of T-DXd. Based on data review, adjudicated ILD/pneumonitis onset occurred earlier than identified by investigators for 53.2% of events [median difference in onset date, 43 (range, 1-499) days]. Stepwise Cox regression identified several baseline factors potentially associated with increased risk of adjudicated drug-related ILD/pneumonitis: age <65 years, enrollment in Japan, T-DXd dose >6.4 mg/kg, oxygen saturation <95%, moderate/severe renal impairment, presence of lung comorbidities, and time since initial diagnosis >4 years. Conclusions In this pooled analysis of heavily treated patients, the incidence of ILD/pneumonitis was 15.4%, with most being low grade and occurring in the first 12 months of treatment. The benefit–risk of T-DXd treatment is positive; however, some patients may be at increased risk of developing ILD/pneumonitis, and further investigation is needed to confirm ILD/pneumonitis risk factors. Close monitoring and proactive management of ILD/pneumonitis are warranted for all. Interstitial lung disease (ILD)/pneumonitis is a significant adverse event related to trastuzumab deruxtecan (T-DXd). This pooled analysis of nine T-DXd monotherapy studies evaluated ILD/pneumonitis risk in 1150 heavily pretreated patients. Overall incidence of adjudicated T-DXd-related ILD/pneumonitis was 15.4% (grade 1 or 2, 77.4%; grade 5, 2.2%). Within 12 months of their first T-DXd dose, 87.0% of patients had their first event [median, 5.4 (range, <0.1-46.8) months]. Proactive monitoring and prompt diagnosis and management are important to improving ILD/pneumonitis event outcomes.
Collapse
Affiliation(s)
- C A Powell
- Catherine and Henry J. Gaisman Division of Pulmonary Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
| | - S Modi
- Memorial Sloan Kettering Cancer Center, New York, USA
| | - H Iwata
- Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
| | - S Takahashi
- Medical Oncology, The Cancer Institute Hospital of JFCR, Koto, Tokyo, Japan
| | - E F Smit
- Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S Siena
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - D-Y Chang
- National Taiwan University Hospital, Taipei City, Taiwan
| | | | - A Qin
- Daiichi Sankyo Inc., Basking Ridge, USA
| | - J Singh
- Daiichi Sankyo Inc., Basking Ridge, USA
| | - C Taitt
- Daiichi Sankyo Inc., Basking Ridge, USA
| | - N Shire
- AstraZeneca Pharmaceuticals, Gaithersburg, USA
| | | |
Collapse
|
6
|
Chen S, Peng Y, Liu Y, Zhao C, Deng X, Qin A, Yan D, Stevens C, Deraniyagala R, Ding X. PO-1503 MRI-based Synthetic CT images for IMPT Treatment Planning of Nasopharyngeal Carcinoma Patients. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03467-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Liu G, Zhao L, Qin A, Deraniyagala R, Stevens C, Yan D, Li X, Ding X. Lung Stereotactic Body Radiotherapy (SBRT) Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Qin A, Snyder M, Liang J, Chen S, Yan D. Achievable Accuracy of DIR for Tumor/Organ With Large Progressive Shrinkage During the Radiation Treatment: A Bio-Tissue Phantom Study. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Chen S, Yan D, Qin A. Predictive Capability and Dynamic Characteristic of Tumor Voxel Dose-Response Assessed Using 18F-FDG PET/CT Imaging Feedback. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Qin A, Lima F, Bell S, Kalemkerian G, Schneider B, Ramnath N, Lew M, Rao A, Frankel T. P57.03 Cellular Engagement and Interaction in the Tumor Microenvironment (TME) Predicts Response to ICI in Metastatic NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.575] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Ding X, Chang S, Liu G, Zhao L, Zheng W, Qin A, Di Y, Li X. PO-1842 Introduce a new rotational robust optimized Spot-scanning Proton Arc (SPArc) framework. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08293-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Powell C, Modi S, Iwata H, Takahashi S, Nie K, Qin A, Singh J, Taitt C, Verma S, Camidge D. 92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.106] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
13
|
Qin A, Chen S, Liu G, Li X, Zheng W, Deraniyagala R, Kabolizadeh P, Stevens C, Yan D, Ding X. The Feasibility and Accuracy of Utilizing CBCT and Generative-Adversarial-Network (GAN) to Perform Proton Treatment Dose Evaluation for Lung and Head and Neck Patients. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Liu G, Qin A, Zhou J, Yan D, Zhao L, Stevens C, Grills I, Kabolizadeh P, Li X, Ding X. PO-1759: A dose validation tool prior to proton and photon treatment in spine SRS. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01777-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Powell C, Camidge D, Modi S, Qin A, Taitt C, Lee C, Hackshaw M, Singh J, Iwata H. 289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.391] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
16
|
Green M, Rosen B, Qin A, Wilkie J, Jaworski L, Journey S, Matuszak M, Haken RKT, Lawrence T, Zou W, Schonewolf C, Jolly S, Ramnath N, El Naqa I. FDG PET-CT Quantitative Features Predict Immune Checkpoint Blockade Efficacy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Lin X, Chen J, Qiu P, Zhang Q, Wang S, Su M, Chen Y, Jin K, Qin A, Fan S, Chen P, Zhao X. Biphasic hierarchical extracellular matrix scaffold for osteochondral defect regeneration. Osteoarthritis Cartilage 2018; 26:433-444. [PMID: 29233641 DOI: 10.1016/j.joca.2017.12.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Revised: 11/25/2017] [Accepted: 12/04/2017] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To investigate the effect of decellularized osteochondral extracellular matrix (ECM) scaffold for osteochondral defect regeneration. DESIGN We compared the histological features and microstructure of degenerated cartilage to normal articular cartilage. We also generated and evaluated osteochondral ECM scaffolds through decellularization technology. Then scaffolds were implanted to osteochondral defect in rabbit model. After 12 weeks surgery, regeneration tissues were analyzed by histology, immunohistochemistry evaluation. And possible mechanisms of angiogenesis and cell migration were explored. RESULTS We demonstrated decreased cell numbers, formation of fibrous cartilage, lost microstructure and worse permeability in degenerated cartilage compared to normal cartilage. We also generated an osteochondral ECM scaffold with a hierarchical structure that exhibited low immunogenicity, high bioactivity, and well biocompatibility. We found that the ECM scaffold promoted tissue regeneration in osteochondral defects, which was dependent on the scaffold constituents and stratified three-dimensional microstructure as well as on its ability to inhibit angiogenesis and stimulate cell migration. CONCLUSIONS Our findings demonstrated that the biphasic hierarchical ECM scaffold represents a novel and effective biomaterial that can be used in the treatment of osteochondral defect.
Collapse
Affiliation(s)
- X Lin
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China
| | - J Chen
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China
| | - P Qiu
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China
| | - Q Zhang
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China
| | - S Wang
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China
| | - M Su
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China
| | - Y Chen
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China
| | - K Jin
- Department of Pathophysiology, Wenzhou Medical University, Wenzhou, China
| | - A Qin
- Department of Orthopedics, Shanghai Key Laboratory of Orthopedic Implant, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - S Fan
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China.
| | - P Chen
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China.
| | - X Zhao
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China.
| |
Collapse
|
18
|
Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol 2017; 28:541-546. [PMID: 28426120 PMCID: PMC5391707 DOI: 10.1093/annonc/mdw659] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Background This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively). Patients and methods Patients received olaratumab 20 mg/kg intravenously every 14 days until disease progression, death, or intolerable toxicity occurred. Outcome measures were 12-week tumor response, progression-free survival (PFS), overall survival (OS), and safety. Results Of 30 patients enrolled, 21 patients received ≥1 dose of olaratumab. In the evaluable population (cohort 1, n = 6; cohort 2, n = 14), no complete response (CR) or partial response (PR) was observed. Stable disease (SD) was observed in 3 patients (50.0%) in cohort 1 and 2 patients (14.3%) in cohort 2. Progressive disease (PD) was observed in 3 patients (50.0%) in cohort 1 and 12 patients (85.7%) in cohort 2. The 12-week clinical benefit rate (CR + PR + SD) (90% CI) was 50.0% (15.3–84.7%) in cohort 1 and 14.3% (2.6–38.5%) in cohort 2. SD lasted beyond 12 weeks in 5 patients (cohort 1, n = 3; cohort 2, n = 2). Median PFS (90% CI) was 32.1 (5.0–35.9) weeks in cohort 1 and 6.1 (5.7–6.3) weeks in cohort 2. Median OS was not reached in cohort 1 and was 24.9 (14.4–49.1) weeks in cohort 2. All patients in cohort 1 and 9 (64.3%) in cohort 2 experienced an olaratumab-related adverse event (AE), most commonly fatigue (38.1%), nausea (19.0%), and peripheral edema (14.3%). Two grade ≥3 olaratumab-related events were reported (cohort 1, syncope; cohort 2, hypertension). Conclusions Olaratumab had an acceptable AE profile in patients with GIST. While there was no apparent effect on PFS in patients without PDGFRα mutations, patients with PDGFRα-mutant GIST (all with D842V mutations) treated with olaratumab had longer disease control compared with historical data for this genotype. ClinicalTrials.gov Identifier NCT01316263.
Collapse
Affiliation(s)
- A J Wagner
- Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston
| | - H Kindler
- University of Chicago Medical School, Chicago, USA
| | - H Gelderblom
- Leids Universitair Medisch Centrum, Leiden, Netherlands
| | - P Schöffski
- Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - S Bauer
- West German Cancer Center, University of Duisburg-Essen, Essen, and German Cancer Consortium, Heidelberg
| | - P Hohenberger
- Division of Surgical Oncology and Thoracic Surgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim
| | - H-G Kopp
- Department of Oncology and Hematology, Tuebingen University Medical Center, Tuebingen, Germany
| | - J A Lopez-Martin
- 12 de Octubre University Hospital and Research Institute, Madrid, Spain
| | - M Peeters
- Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
| | - P Reichardt
- HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - A Qin
- Eli Lilly and Company, Indianapolis, USA
| | - J Nippgen
- Merck KGaA (Formerly ImClone Medical), Darmstadt, Germany
| | - R L Ilaria
- Eli Lilly and Company, Indianapolis, USA
| | - P Rutkowski
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| |
Collapse
|
19
|
Hauck C, Qin A, Liang J, Ye H, Krauss D, Grills I, Chen P, Yan D. Factors Associated With Organ Geometric and Treatment Dose Variations Identified During PET-CT-Based Adaptive Head and Neck Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Qin A, Street L, Viglianti B, Cease K, Warren E, Ramnath N. Clinical Predictors of Durable Clinical Benefit of Pembrolizumab Therapy in Veterans With Metastatic Non–Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.01.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Tap W, Jones R, Chmielowski B, Elias A, Adkins D, Van Tine B, Agulnik M, Cooney M, Livingston M, Pennock G, Qin A, Shahir A, Ilaria R, Conti I, Schwartz G. A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor &agr; (pdgfr&agr;) monoclonal antibody, in advanced soft tissue sarcoma (sts). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw343.01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Ionascu D, Castillo E, Qin A, Solis D, Lack D, Sandhu R, Yee S, Guerrero T. TU-AB-202-09: Performance of Cross-Modality DIR Algorithms Using Images Computed from a Novel, Tissue-Like Phantom Capable of Reproducible Degrees of Deformation. Med Phys 2016. [DOI: 10.1118/1.4957431] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
23
|
Li X, Zhang J, Qin A, Liang J, Zhou J, Yan D, Chen P, Krauss D, Ding X. SU-F-T-205: Effectiveness of Robust Treatment Planning to Account for Inter- Fractional Variation in Intensity Modulated Proton Therapy for Head Neck Cancer. Med Phys 2016. [DOI: 10.1118/1.4956342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
24
|
Zhu J, Liang J, Chen S, Qin A, Yan D. SU-F-J-86: Method to Include Tissue Dose Response Effect in Deformable Image Registration. Med Phys 2016. [DOI: 10.1118/1.4955994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
25
|
Liu G, Qin A, Zhang J, Li X, Zhou J, Yan D, Teo B, Chen P, Krauss D, Kabolizadeh P, Guerrero T, Stevens C, Liang J, Ding X. SU-F-J-192: A Quick and Effective Method to Validate Patient's Daily Setup and Geometry Changes Prior to Proton Treatment Delivery Based On Water Equivalent Thickness Projection Imaging (WETPI) for Head Neck Cancer (HNC) Patient. Med Phys 2016. [DOI: 10.1118/1.4956100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
26
|
|
27
|
Sandhu R, Qin A, Yan D. SU-E-J-67: Evaluation of Adaptive MLC Morphing for Online Correction of Prostate Cancer Radiotherapy. Med Phys 2015. [DOI: 10.1118/1.4924154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
28
|
Li G, Ma Y, Cheng TS, Landao-Bassonga E, Qin A, Pavlos NJ, Zhang C, Zheng Q, Zheng MH. Identical subchondral bone microarchitecture pattern with increased bone resorption in rheumatoid arthritis as compared to osteoarthritis. Osteoarthritis Cartilage 2014; 22:2083-92. [PMID: 25205016 DOI: 10.1016/j.joca.2014.08.015] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Revised: 08/21/2014] [Accepted: 08/29/2014] [Indexed: 02/02/2023]
Abstract
OBJECTIVES To analyze the differences in microarchitecture and bone remodeling of subchondral bone in femoral heads from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). DESIGNS Peri-articular bone samples, including subchondral trabecular bone (STB) and deeper trabecular bone (DTB) were extracted from the load-bearing region of femoral heads from 20 patients with RA and 40 patients with OA during hip replacement surgery. Micro-CT, histomorphometry and backscatter scanning electron microscopy (BSEM) were performed to assess microarchitecture and bone histology parameters. RESULTS In both RA and OA, STB showed more sclerotic microarchitecture and more active bone remodeling, compared to DTB. RA and OA showed similar microarchitecture characteristics in both STB and DTB, despite STB in RA exhibiting higher bone resorption. In addition, there was no difference in the frequency of bone cysts in STB between RA and OA. In STB, the trabecular bone surrounding subchondral bone cysts (Cys-Tb) was more sclerotic than the trabecular bone found distant to cysts (Peri-Tb), with a higher level of bone remodeling. Both Cys-Tb region and Peri-Tb region were detected to have similar microarchitectural and bone remodeling characteristics in RA and OA. CONCLUSIONS Apart from higher bone resorption in the general subchondral bone of RA samples, the peri-articular bone exhibited similar microarchitectural and bone remodeling characteristics in RA and OA.
Collapse
Affiliation(s)
- G Li
- Department of Orthopaedics, Shanghai Jiao Tong University Affiliated the Sixth People's Hospital, Shanghai, China; Centre for Orthopaedic Research, School of Surgery, The University of Western Australia, Perth, Australia.
| | - Y Ma
- Division of Orthopaedic Surgery, Guangdong General Hospital, Guangzhou, China.
| | - T S Cheng
- Centre for Orthopaedic Research, School of Surgery, The University of Western Australia, Perth, Australia.
| | - E Landao-Bassonga
- Centre for Orthopaedic Research, School of Surgery, The University of Western Australia, Perth, Australia.
| | - A Qin
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - N J Pavlos
- Centre for Orthopaedic Research, School of Surgery, The University of Western Australia, Perth, Australia.
| | - C Zhang
- Department of Orthopaedics, Shanghai Jiao Tong University Affiliated the Sixth People's Hospital, Shanghai, China.
| | - Q Zheng
- Division of Orthopaedic Surgery, Guangdong General Hospital, Guangzhou, China.
| | - M H Zheng
- Centre for Orthopaedic Research, School of Surgery, The University of Western Australia, Perth, Australia.
| |
Collapse
|
29
|
Zhai ZJ, Li HW, Liu GW, Qu XH, Tian B, Yan W, Lin Z, Tang TT, Qin A, Dai KR. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br J Pharmacol 2014; 171:663-75. [PMID: 24125472 DOI: 10.1111/bph.12463] [Citation(s) in RCA: 92] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2013] [Revised: 09/25/2013] [Accepted: 09/27/2013] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND AND PURPOSE Osteoclasts play a pivotal role in diseases such as osteoporosis, rheumatoid arthritis and tumour bone metastasis. Thus, searching for natural compounds that may suppress osteoclast formation and/or function is promising for the treatment of osteoclast-related diseases. Here, we examined changes in osteoclastogenesis and LPS-induced osteolysis in response to andrographolide (AP), a diterpenoid lactone isolated from the traditional Chinese and Indian medicinal plant Andrographis paniculata. EXPERIMENTAL APPROACH Effects of AP on osteoclast differentiation and bone resorption were measured in vitro. Western blots and RT-PCR techniques were used to examine the underlying molecular mechanisms. The bone protective activity of AP in vivo was assessed in a mouse model of osteolysis. KEY RESULTS AP concentration-dependently suppressed RANKL-mediated osteoclast differentiation and bone resorption in vitro and reduced the expression of osteoclast-specific markers, including tartrate-resistant acid phosphatase, calcitonin receptors and cathepsin K. Further molecular analysis revealed that AP impaired RANKL-induced NF-κB signalling by inhibiting the phosphorylation of TGF-β-activated kinase 1, suppressing the phosphorylation and degradation of IκBα, and subsequently preventing the nuclear translocation of the NF-κB p65 subunit. AP also inhibited the ERK/MAPK signalling pathway without affecting p38 or JNK signalling. CONCLUSIONS AND IMPLICATIONS AP suppressed RANKL-induced osteoclastogenesis through attenuating NF-κB and ERK/MAPK signalling pathways in vitro, thus preventing bone loss in vivo. These data indicated that AP is a promising natural compound for the treatment of osteoclast-related bone diseases.
Collapse
Affiliation(s)
- Z J Zhai
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
Goose parvovirus (GPV) causes high mortality and morbidity in goslings and Muscovy ducklings. In this study, a GPV was isolated from a 20-day old swan in Shanghai, China. Complete genome of the swan isolate contained 5,050 nt and showed the highest homology with Taiwanese GPV isolates from 1982. In comparison with the Chinese mainland GPV isolates reported previously, the swan isolate shows two deletions, particularly at positions 67-80 and 334-347 in inverted terminal repeats (ITRs). These findings suggest that the swan could serve as a potential host for GPV and provide insights into molecular characteristics and etiology of GPV.
Collapse
|
31
|
Sandhu R, Qin A, Yan D. SU-E-J-20: Adaptive Aperture Morphing for Online Correction for Prostate Cancer Radiotherapy. Med Phys 2014. [DOI: 10.1118/1.4888071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
32
|
Qin A, Yan D. MO-C-17A-13: Uncertainty Evaluation of CT Image Deformable Registration for H&N Cancer Adaptive Radiotherapy. Med Phys 2014. [DOI: 10.1118/1.4889135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Chen X, Hu X, Yu C, Qian K, Ye J, Qin A. Differential protein analysis of chicken skin infected with Marek΄s disease virus. Acta Virol 2014; 58:43-52. [PMID: 24717028 DOI: 10.4149/av_2014_01_43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The skin and feather follicle epithelia of birds infected with Marek's disease virus (MDV) are the sites of infectious virus particle formation and shedding. However, the host responses and protein networks involved in the production of virus particles in the skin of MDV-infected chickens are poorly understood. This current study aimed to analyze the differential protein expression patterns in skin between MDV-infected and uninfected specific pathogen-free (SPF) chickens 28 days post infection (dpi) by combining two-dimensional electrophoresis (2-DE) and mass spectrometry (MS) analyses. Through 2-DE analysis, our results revealed 23 proteins whose expression changed significantly following infection, of which 16 proteins were confirmed by MS. The identified proteins were functionally classified into 5 groups: immune-related, cell regulatory, cytoskeletal, metabolism-related and transport proteins. A single protein, beta 2-microglobulin, was further confirmed by real-time quantitative PCR. Beta 2-microglobulin expression was significantly increased in the infected group 28 dpi. This indicates that beta 2-microglobulin might play very important roles in the viral evasion from host immune response.
Collapse
|
34
|
Jiang T, Qin A, Shao Z, Tian B, Zhai Z, Li H, Zhu Z, Dai K, Ming HZ, Yu Y, Jiang Q. OA10 Is a Novel p38alpha Mitogen-Activated Protein Kinase Inhibitor That Suppresses Osteoclast Differentiation and Bone Resorption. J Cell Biochem 2014; 115:959-66. [PMID: 24357524 DOI: 10.1002/jcb.24744] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Accepted: 12/05/2013] [Indexed: 11/10/2022]
Affiliation(s)
- T. Jiang
- The Center of Diagnosis and Treatment for Joint Disease; Drum Tower Clinical Medical College of Nanjing Medical University; Jiangsu P.R. China
| | - A. Qin
- Centre for Orthopaedic Research, School of Surgery; The University of Western Australia; Perth Australia
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics; Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai P.R. China
| | - Z.Y. Shao
- College of Pharmaceutical Sciences; Zhejiang University; Hangzhou P.R. China
| | - B. Tian
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics; Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai P.R. China
| | - Z.J. Zhai
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics; Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai P.R. China
| | - H.W. Li
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics; Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai P.R. China
| | - Z.A. Zhu
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics; Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai P.R. China
| | - K.R. Dai
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics; Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai P.R. China
| | - H. Zheng Ming
- Centre for Orthopaedic Research, School of Surgery; The University of Western Australia; Perth Australia
| | - Y.P. Yu
- College of Pharmaceutical Sciences; Zhejiang University; Hangzhou P.R. China
| | - Q. Jiang
- The Center of Diagnosis and Treatment for Joint Disease; Drum Tower Clinical Medical College of Nanjing Medical University; Jiangsu P.R. China
| |
Collapse
|
35
|
Tian B, Qin A, Shao Z, Jiang T, Zhai Z, Li H, Tang T, Jiang Q, Dai K, Zheng M, Yu Y, Zhu Z. OA-4 Inhibits Osteoclast Formation and Bone Resorption via Suppressing RANKL Induced P38 Signaling Pathway. Curr Med Chem 2014; 21:641-9. [DOI: 10.2174/09298673113209990190] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2013] [Revised: 06/24/2013] [Accepted: 07/23/2013] [Indexed: 11/22/2022]
|
36
|
Sheng J, Qu X, Zhang X, Zhai Z, Li H, Liu X, Li H, Liu G, Zhu Z, Hao Y, Qin A, Dai K. Coffee, tea, and the risk of hip fracture: a meta-analysis. Osteoporos Int 2014; 25:141-50. [PMID: 24196722 DOI: 10.1007/s00198-013-2563-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Accepted: 10/16/2013] [Indexed: 10/26/2022]
Abstract
UNLABELLED The present meta-analysis shows no clear association between coffee consumption and the risk of hip fractures. There was a nonlinear association between tea consumption and the risk of hip fracture. Compared to no tea consumption, drinking 1-4 cups of tea daily was associated with a lower risk of hip fracture. INTRODUCTION Prospective cohort and case-control studies have suggested that coffee and tea consumption may be associated with the risk of hip fracture; the results have, however, been inconsistent. We conducted a meta-analysis to assess the association between coffee and tea consumption and the risk of hip fracture. METHODS We performed systematic searches using MEDLINE, EMBASE, and OVID until February 20, 2013, without limits of language or publication year. Relative risks (RRs) with 95% confidence intervals (CI) were derived using random-effects models throughout all analyses. We conducted categorical, dose-response, heterogeneity, publication bias, and subgroup analyses. RESULTS Our study was based on 195,992 individuals with 9,958 cases of hip fractures from 14 studies, including six cohort and eight case-control studies. The pooled RRs of hip fractures for the highest vs. the lowest categories of coffee and tea consumption were 0.94 (95% CI 0.71-1.17) and 0.84 (95% CI 0.66-1.02), respectively. For the dose-response analysis, we found evidence of a nonlinear association between tea consumption and the risk of hip fracture (p(nonlinearity) < 0.01). Compared to no tea consumption, 1-4 cups of tea per day may reduce the risk of hip fracture by 28% (0.72; 95% CI 0.56-0.88 for 1-2 cups/day), 37% (0.63; 95% CI 0.32-0.94 for 2-3 cups/day), and 21% (0.79; 95% CI 0.62-0.96 for 3-4 cups/day). CONCLUSIONS We found no significant association between coffee consumption and the risk of hip fracture. A nonlinear association emerged between tea consumption and the risk of hip fracture; individuals drinking 1-4 cups of tea per day exhibited a lower risk of hip fractures than those who drank no tea. The association between 5 daily cups of tea, or more, and hip fracture risk should be investigated.
Collapse
Affiliation(s)
- J Sheng
- Department of Geriatrics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Qin A, Sun Y, Liang J, Yan D. Evaluation of 3 IGRT/Adaptive Approaches for Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Qin A, Sun Y, Liang J, Tyagi N, Yan D. SU-C-103-03: Online CBCT Guided Prostate Cancer Radiotherapy: Is 3 Mm Target Margin Adequate? Med Phys 2013. [DOI: 10.1118/1.4813970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
39
|
Qin A, Liang J, Yan D. TH-A-BRA-04: Evaluation of Three IGRT Approaches for Prostate Cancer Treatment. Med Phys 2012. [DOI: 10.1118/1.4736253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
40
|
Qin A, Cheng TS, Pavlos NJ, Lin Z, Dai KR, Zheng MH. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol 2012; 44:1422-35. [PMID: 22652318 DOI: 10.1016/j.biocel.2012.05.014] [Citation(s) in RCA: 102] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2012] [Revised: 05/18/2012] [Accepted: 05/18/2012] [Indexed: 01/06/2023]
Abstract
The vacuolar-type H(+)-ATPase (V-ATPase) proton pump is a macromolecular complex composed of at least 14 subunits organized into two functional domains, V(1) and V(0). The complex is located on the ruffled border plasma membrane of bone-resorbing osteoclasts, mediating extracellular acidification for bone demineralization during bone resorption. Genetic studies from mice to man implicate a critical role for V-ATPase subunits in osteoclast-related diseases including osteopetrosis and osteoporosis. Thus, the V-ATPase complex is a potential molecular target for the development of novel anti-resorptive agents useful for the treatment of osteolytic diseases. Here, we review the current structure and function of V-ATPase subunits, emphasizing their exquisite roles in osteoclastic function. In addition, we compare several distinct classes of V-ATPase inhibitors with specific inhibitory effects on osteoclasts. Understanding the structure-function relationship of the osteoclast V-ATPase may lead to the development of osteoclast-specific V-ATPase inhibitors that may serve as alternative therapies for the treatment of osteolytic diseases.
Collapse
Affiliation(s)
- A Qin
- Centre for Orthopaedic Research, School of Surgery, The University of Western Australia, Crawley, Australia.
| | | | | | | | | | | |
Collapse
|
41
|
Mei J, Wang J, Qin A, Zhao H, Yuan W, Zhao Z, Sung HHY, Deng C, Zhang S, Williams ID, Sun JZ, Tang BZ. Construction of soft porous crystal with silole derivative: strategy of framework design, multiple structural transformability and mechanofluorochromism. ACTA ACUST UNITED AC 2012. [DOI: 10.1039/c1jm12673c] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
42
|
Qin A, Liang J, Yan D. Hybrid CBCT Image Deformable Organ Registration for Prostate Cancer Radiotherapy Dose Assessment: Quantitative Validation Study. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1444] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Martell RE, Chiorean EG, Youssoufian H, Rutstein MD, Pytowski B, Benjamin L, Abad L, Patel J, Steele T, Dowd M, Qin A, Kukel CF, Fox FE, Dontabhaktuni A, Morozov A. Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps150] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Shi D, Zheng Q, Chen D, Zhu L, Qin A, Fan J, Liao J, Xu Z, Lin Z, Norman P, Xu J, Nakamura T, Dai K, Zheng M, Jiang Q. Association of single-nucleotide polymorphisms in HLA class II/III region with knee osteoarthritis. Osteoarthritis Cartilage 2010; 18:1454-7. [PMID: 20691797 DOI: 10.1016/j.joca.2010.07.009] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2010] [Revised: 07/18/2010] [Accepted: 07/20/2010] [Indexed: 02/02/2023]
Abstract
OBJECTIVE A genome-wide association study and a replication using Japanese, Spanish and Greek Caucasian populations have recently indicated two single-nucleotide polymorphisms (SNPs) (rs7775228 and rs10947262) associated with knee Osteoarthritis (OA) susceptibility. We have further evaluated the association in knee OA subjects from Han Chinese and Australian Caucasian origin. METHODS Two independent case-control association studies were performed using Han Chinese and Australian Caucasian populations. The two SNPs were genotyped in patients who had primary symptomatic knee OA with radiographic confirmation and/or received total knee replacement surgery as well as in matched controls. They were subjected to statistic analyses. RESULTS A total of 991 OA patients and 1536 controls were genotyped. No significant difference was detected in genotype or allele frequencies of the two SNPs between knee OA and control groups in the two populations (all P>0.05). The association was also negative even after stratification by sex, body mass index (BMI) and Kellgren/Lawrence scores. The significant heterogeneity was detected between Chinese and Japanese (both P<0.05). In the Caucasian samples, no significant heterogeneity was detected (both P>0.05). The result of meta-analysis showed significant association between knee OA and rs10947262 in total subjects [summary OR=1.26, 95%confidence intervals (CI)=1.07-1.27, P=3 × 10(-8)] and in Caucasian samples (summary OR=1.28, 95%CI=1.04-1.57, P=0.02). CONCLUSION We demonstrated no association between the two SNPs in human leukocyte antigen (HLA) class II/III region and knee OA in Han Chinese population. A significant association was detected between SNP rs10947262 and knee OA in Caucasian subjects. Further replication studies are required to identify the impact of controversial association.
Collapse
Affiliation(s)
- D Shi
- The Center of Diagnosis and Treatment for Joint Disease, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing 210008, Jiangsu, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Qin A, Liang J, Yan D. MO-FF-A4-06: A Hybrid Deformable Registration Method between Helical CT and Cone-Beam CT for Prostate Patient. Med Phys 2010. [DOI: 10.1118/1.3469160] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
46
|
Thompson DS, Patnaik A, Bendell JC, Papadopoulos K, Infante JR, Mastico RA, Johnson D, Qin A, O'Leary JJ, Tolcher AW. A phase I dose-escalation study of IMGN388 in patients with solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3058] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Goff LW, Papadopoulos K, Posey JA, Phan AT, Patnaik A, Miller JG, Zildjian S, O'Leary JJ, Qin A, Tolcher A. A phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal (GE) junction cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15625] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15625 Background: IMGN242 is a conjugate of the cytotoxic maytansinoid DM4 and the monoclonal antibody huC242, which binds to CanAg. In a Phase I study, the maximum tolerated dose for IMGN242 was determined to be 168 mg/m2, with ocular changes the primary dose-limiting toxicity. This Phase II study was initiated to assess IMGN242 for the treatment of gastric cancer. Methods: In this open-label, multi-center study, IMGN242 is given as a single IV infusion every three weeks to patients with CanAg-expressing metastatic or locally-advanced gastric or GE junction cancer. Patients must have been treated with at least one prior therapy to qualify for enrollment. The study has a 2-step design: If ≥1 objective response is achieved among the first 23 patients (Step 1), a total of 39 response-evaluable patients will be enrolled (Step 2). Results: Overall, 9 patients have received IMGN242. The first 6 were treated with 168 mg/m2, and 1 of these patients showed a marked biologic response by the FDG-PET scan in Cycle 1 followed by an unconfirmed partial response based on CT scan in Cycle 2. However, 3 of these 6 patients developed ocular toxicities assessed to be study drug related. Only patients with low plasma CanAg levels (<1000 U/ml) developed ocular toxicities, and clinical pharmacokinetic and pharmacodynamic (PK/PD) analyses revealed that plasma CanAg affects study drug exposures. The study was amended to differentiate the IMGN242 doses (126 mg/m2 or 168 mg/m2) administered based on the patient's plasma CanAg levels (< or >1000 U/mL). To date, 3 patients have received IMGN242 with this dosing strategy and no ocular toxicities have been reported. Conclusions: IMGN242 showed preliminary evidence of activity in this patient population. A novel Phase II dosing strategy is being used that should enhance tolerability. Patient enrollment is ongoing and updated results will be reported. [Table: see text]
Collapse
Affiliation(s)
- L. W. Goff
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - K. Papadopoulos
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - J. A. Posey
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - A. T. Phan
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - A. Patnaik
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - J. G. Miller
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - S. Zildjian
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - J. J. O'Leary
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - A. Qin
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| | - A. Tolcher
- Vanderbilt-Ingram Cancer Center, Nashville, TN; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Alabama Comprehensive Cancer Center, Birmingham, AL; M. D. Anderson Cancer Center, Houston, TX; ImmunoGen, Inc., Waltham, MA
| |
Collapse
|
48
|
Woll P, Fossella F, O'Brien M, Clinch Y, Donaldson K, O'Keeffe J, Zildjian S, Fram R, Qin A, Lorigan P. 510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72444-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
49
|
Qin A, Watermill J, Mastico RA, Lutz RJ, O'Keeffe J, Zildjian S, Mita AC, Phan AT, Tolcher AW. The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3066] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Mita MM, Ricart AD, Mita AC, Patnaik A, Sarantopoulos J, Sankhala K, Fram RJ, Qin A, Watermill J, Tolcher AW. A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3062] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3062 Background: HuC242-DM4 is a novel, targeted anti-cancer agent in development for the treatment of CanAg-expressing tumors such as carcinomas of the colon and pancreas. The compound is formed by the conjugation of the potent cytotoxic maytansinoid drug, DM4, to the humanized monoclonal antibody, huC242. This agent was highly active across a broad spectrum of CanAg-expressing human tumor xenograft models. Methods: Patients were enrolled with metastatic or inoperable colorectal, pancreatic, and other CanAg-expressing tumors who have failed standard therapy (about 95% of pts. had received = 4 prior chemotherapy regimens). Results: Thirty patients were treated with huC242-DM4, receiving a single intravenous (IV) infusion once every three weeks. Cohorts of 3 patients initially were enrolled on each dose level. Patients have received huC242-DM4 at 18, 36, 60, 90, 126, 168, 223, and 297 mg/m2. To date, dose limiting toxicity (DLT) was experienced by two of six patients treated at the 223 mg/m2 dose level during their second cycle of treatment. The patients experienced decreased visual acuity, corneal deposits and keratitis. Both patients were subsequently treated with lubricating eye drops. At present, these adverse events have markedly improved in one patient, while the other patient has completely returned to baseline. Of 10 patients treated at the168 mg/m2 dose level (including two patients who were dose reduced to 168 mg/m2), seven patients have received at least two cycles of treatment. One patient had grade 3 diarrhea and dehydration during his second cycle at 168 mg/m2. The latter improved with intravenous fluids. Preliminary pharmacokinetic data reveal a half-life of huC242-DM4 of about 5 days in patients with low plasma CanAg levels. In patients with high plasma CanAg levels (>900 units/mL), clearance of huC242-DM4 is increased. There has been no clinically significant myelosuppression and no formation of antibody to humanized antibody (HAHA) or drug (HADA). One patient had a 36% decline in CEA (not associated with tumor shrinkage). Conclusions: HuC242-DM4 was well tolerated at the 168 mg/m2 dose level. The MTD is not yet defined and approaches to prevent /ameliorate ocular toxicity are planned. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. M. Mita
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. D. Ricart
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. C. Mita
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. Patnaik
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - J. Sarantopoulos
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - K. Sankhala
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - R. J. Fram
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. Qin
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - J. Watermill
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. W. Tolcher
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| |
Collapse
|